Richard J. Lewis
Corporate Officer/Principal bei The University of Queensland
Aktive Positionen von Richard J. Lewis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| The University of Queensland | Corporate Officer/Principal | 01.07.2009 | - |
| National Health & Medical Research Council | Corporate Officer/Principal | 01.07.2009 | - |
Karriereverlauf von Richard J. Lewis
Ehemalige bekannte Positionen von Richard J. Lewis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Corporate Officer/Principal | 01.07.2009 | - |
Xenome Ltd.
 Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2000 | - |
| Gründer | 08.02.2010 | - |
Statistik
International
| Australien | 4 |
| Vereinigte Staaten | 2 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
Sektoral
| Health Technology | 2 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MOLECULAR PHARMACOLOGY (USA), LTD. | Commercial Services |
| Private Unternehmen | 2 |
|---|---|
Xenome Ltd.
Xenome Ltd. Pharmaceuticals: MajorHealth Technology Xenome Ltd. discovered and developed peptide pharmaceuticals. Its product, Xen2174, was a novel conopeptide analogue for the treatment of severe pain. The company was founded in 2008 and was headquartered in Indooroopilly, Australia. | Health Technology |
| National Health & Medical Research Council | Government |
- Börse
- Insiders
- Richard J. Lewis
- Erfahrung
